KLK3 and prostate carcinoma: In this context, the widely used prostate specific antigen (PSA) biomarker, tested in an equally heterogenous human population, was originally introduced with a predictive value of 28–35%[34] based on the rationale that there was no other minimally invasive option for early detection of prostate cancer at that time, which is true for CAN today.